Morgan Stanley analyst Tejas Savant maintained a Buy rating on Natera (NTRA – Research Report) today and set a price target of $185.00.
Tejas Savant has given his Buy rating due to a combination of factors that highlight Natera’s strong financial performance and growth potential. The company’s fourth-quarter revenue exceeded preliminary expectations, driven by significant increases in testing volume and average selling prices (ASPs). This marks the fourth consecutive quarter of positive cash flow, showcasing the company’s ability to generate sustainable profits.
Furthermore, Natera’s gross margin improved significantly, attributed to strong ASPs and cost reductions, which further bolstered the company’s financial health. The outlook for 2025 is promising, with guidance surpassing market expectations and potential for further growth through increased adoption of their Signatera test, favorable biomarker legislation, and new product launches. The positive developments in oncology and women’s health sectors also contribute to the optimistic future prospects, reinforcing the Buy rating.
According to TipRanks, Savant is an analyst with an average return of -5.3% and a 37.42% success rate. Savant covers the Healthcare sector, focusing on stocks such as Stevanato Group, Charles River Labs, and Pacific Biosciences.
In another report released today, BTIG also maintained a Buy rating on the stock with a $190.00 price target.